← Back to Screener
Prothena Corporation plc Ordinary Shares (PRTA)
Price$9.59
Value ScoreB
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-14.64%
Price vs S&P 500 (4W)-9.30%
VGM Score66.20
Market Capitalization$532.96M
All Metrics
Book Value / Share (Quarterly)$5.89
P/TBV (Annual)1.02x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-43.57%
Cash Flow / Share (Quarterly)$-1.53
Price vs S&P 500 (YTD)-4.34%
Net Profit Margin (TTM)-260.92%
EPS (TTM)$-2.81
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-2.81
Revenue Growth (5Y)60.83%
EPS (Annual)$-4.53
ROI (Annual)-87.03%
Net Profit Margin (5Y Avg)-591.09%
Cash / Share (Quarterly)$6.21
Revenue Growth QoQ (YoY)1706.36%
ROA (Last FY)-74.69%
Revenue Growth TTM (YoY)-57.99%
EBITD / Share (TTM)$-2.19
ROE (5Y Avg)-28.55%
Operating Margin (TTM)-205.43%
Cash Flow / Share (Annual)$-3.04
P/B Ratio1.70x
P/B Ratio (Quarterly)1.67x
Net Income / Employee (Annual)$-3,643,200
EV / Revenue (TTM)3.51x
Net Interest Coverage (TTM)-1575.00x
ROA (TTM)-42.33%
EV / EBITDA (TTM)3.03x
EPS Incl Extra (Annual)$-4.53
Current Ratio (Annual)7.72x
Quick Ratio (Quarterly)10.25x
3-Month Avg Trading Volume0.50M
52-Week Price Return116.60%
Revenue / Employee (TTM)$864,800
Tangible BV / Share (Quarterly)$6.66
P/S Ratio (Annual)55.03x
Asset Turnover (Annual)0.03x
52-Week High$11.80
Operating Margin (5Y Avg)-549.63%
EPS Excl Extra (Annual)$-4.53
CapEx CAGR (5Y)-7.15%
Tangible BV CAGR (5Y)8.84%
26-Week Price Return1.29%
Quick Ratio (Annual)7.57x
13-Week Price Return17.82%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.43x
Enterprise Value$203.49M
Revenue / Share Growth (5Y)51.42%
Asset Turnover (TTM)0.16x
Book Value / Share Growth (5Y)2.47%
Revenue / Employee (Annual)$144,500
Pretax Margin (Annual)-2073.82%
Cash / Share (Annual)$5.71
3-Month Return Std Dev51.12%
Net Income / Employee (TTM)$-2,256,400
ROE (Last FY)-87.03%
EPS Basic Excl Extra (Annual)$-4.53
P/FCF (TTM)18.46x
Receivables Turnover (TTM)52.40x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.81
Receivables Turnover (Annual)52.40x
ROI (TTM)-49.88%
P/S Ratio (TTM)9.20x
Pretax Margin (5Y Avg)-508.41%
Revenue / Share (Annual)$0.18
Tangible BV / Share (Annual)$7.15
Forward P/E205.71x
Price vs S&P 500 (52W)88.39%
Year-to-Date Return6.60%
5-Day Price Return3.56%
EPS Normalized (Annual)$-4.53
ROA (5Y Avg)-24.52%
Net Profit Margin (Annual)-2520.57%
Month-to-Date Return-7.96%
Cash Flow / Share (TTM)$-1.36
EBITD / Share (Annual)$-3.97
Operating Margin (Annual)-2216.44%
ROI (5Y Avg)-28.55%
EPS Basic Excl Extra (TTM)$-2.81
P/TBV (Quarterly)1.01x
P/B Ratio (Annual)1.83x
Pretax Margin (TTM)-184.21%
Book Value / Share (Annual)$5.21
Price vs S&P 500 (13W)8.08%
Beta-0.34x
P/FCF (Annual)5.79x
Revenue / Share (TTM)$1.07
ROE (TTM)-49.88%
52-Week Low$4.42
vGradeB
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.61est. -0.36
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.77
3.77
3.75
3.75
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PRTAProthena Corporation plc Ordinary Shares | B | B | B | $9.59 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Prothena is a late-stage clinical biotechnology company developing treatments for neurodegenerative and amyloid diseases using its proprietary CYTOPE platform, which targets intracellular disease pathways in the brain and body. The company's pipeline includes Prasinezumab for Parkinson's disease, Coramitug for ATTR amyloidosis, and partnered programs targeting Alzheimer's disease and ALS. Prothena combines wholly-owned and partnered assets to address protein-dysregulation disorders with significant unmet medical needs.